Shilpa Medicare Peer Comparison

NSE: SHILPAMED | BSE: 530549

₹903.80

₹1.95 (0.22%)

As on 28-Aug-2026IST

Market cap

₹17,751 Cr

Revenue (TTM)

₹1,682 Cr

P/E Ratio

59.7

P/B Ratio

6.6

Div. Yield

0.1 %

Edit

	Shilpa Medicare	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Market cap (₹ Cr)	17,751	21,529	19,158	17,862	18,168
Revenue (₹ Cr)	1,682	2,570	2,287	2,432	3,230
Net Profit (₹ Cr)	273.51	735.15	678.07	169.62	666.92
Net Margin (%)	16.19	26.88	28.10	6.90	20.60
RoE (%)	11.15	19.16	19.73	20.76	18.75
Price to Earnings	59.70	29.29	28.79	105.31	28.22
Price-To-Book	6.61	4.88	5.09	19.75	4.49

Income Statement (₹ Cr)

	Shilpa Medicare	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Operating Revenue	1,538.87	2,519.65	1,937.47	2,275.58	2,893.64
Total Income	1,602.52	2,707.60	2,033.90	2,304.07	2,912.00
Total Expenditure	1,157.98	1,615.47	1,290.54	2,013.55	1,876.44
EBITDA	380.89	904.18	646.93	262.03	1,017.20
Depreciation	119.72	57.73	65.96	28.58	315.46
EBIT	261.17	846.45	580.97	233.45	701.74
Interest	58.79	9.57	0.61	4.49	231.29
Other Income	63.65	187.95	96.43	28.49	18.36
Exceptional Items	12.16	-49.16	--	-5.25	--
Profit before Tax	295.31	975.67	676.78	252.20	488.87
Provision for Tax	51.98	253.24	135.69	64.68	114.20
Profit after Tax	243.33	722.43	541.09	187.52	374.67

	Shilpa Medicare	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Shareholder's Funds	2,591.20	4,202.90	2,850.49	872.79	2,854.36
Minority Interest	1.04	--	35.90	--	417.40
Non-Current Liabilities	249.46	19.19	13.24	394.49	2,100.97
Current Liabilities	848.06	627.48	305.99	1,109.50	1,489.55
Total Liabilities	3,705.61	4,921.88	3,207.85	2,414.58	6,862.28

	Shilpa Medicare	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Non-Current Assets	2,578.95	1,046.35	1,071.67	509.16	5,531.13
Current Assets	1,109.77	3,803.22	2,133.95	1,859.88	1,331.15
Total Assets	3,705.61	4,921.88	3,207.85	2,414.58	6,862.28
Total Debt*	657.97	2.50	0.55	0.00	2,421.66
Net Current Assets	261.71	3,175.74	1,827.96	750.38	-158.40
Contingent Liabilities	160.01	370.49	0.64	121.23	64.29

	Shilpa Medicare	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Cash From Operating Activities	342.18	967.57	432.37	-15.14	1,065.01
Cash Flow from Investing Activities	-325.92	-561.67	-334.73	18.69	-79.97
Cash from Financing Activities	13.62	-798.31	-38.32	-91.97	-881.32
Net Cash Inflow / Outflow	29.88	-392.41	59.32	-88.42	103.72

	Shilpa Medicare	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
ROCE (%)	11.43	23.39	26.22	31.24	13.59
ROE (%)	9.82	17.16	21.72	23.02	13.81
ROA (%)	6.97	14.91	18.37	8.90	5.48
EBIT Margin (%)	28.89	43.34	38.37	12.77	35.79
Net Margin (%)	15.18	26.68	26.60	8.14	12.87
Cash Profit Margin (%)	23.59	29.72	31.33	9.47	23.22

	Shilpa Medicare	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Revenue Growth (%)	19.62	10.45	14.37	32.59	44.02
EBIT Growth (%)	29.72	19.68	20.21	-1.38	48.22
Net Profit Growth (%)	210.81	-5.88	17.27	62.02	-5.65
EPS Growth (%)	210.80	-5.88	17.25	62.02	-10.39
Book Value Growth (%)	9.67	-0.34	23.77	13.51	10.19

	Shilpa Medicare	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Price / Earnings	28.03	29.89	28.38	103.45	54.83
Price / Book Value	2.63	5.14	5.52	22.39	6.78
Dividend Yield (%)	0.17	1.59	0.30	0.46	0.52
EV/EBITDA	16.72	16.93	19.78	65.23	20.75
Market Cap (₹ Cr)	6,819.66	21,592.90	15,219.80	19,398.64	19,292.77

	Shilpa Medicare	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debt to Equity	0.25	0.00	0.00	0.00	0.85
Short term debt to equity ratio	0.16	0.00	0.00	--	0.14
Current Ratio	1.31	6.06	6.97	1.68	0.89
Quick Ratio	0.88	5.31	5.88	0.75	0.67
Interest Coverage	6.02	102.95	1,110.48	57.17	3.11

	Shilpa Medicare	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debtors to sales (%)	33.72	7.22	32.65	9.39	15.85
Asset Turnover	0.44	0.54	0.66	1.08	0.43
Receivable days	113.81	26.06	110.70	31.88	54.07
Inventory Days	84.76	65.95	65.86	126.03	32.16
Payable days	101.94	81.01	105.88	163.79	140.91
Cash Conversion Cycle	96.62	11.00	70.68	-5.88	-54.68

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.